MiRNAs Evaluate the Prognosis of Sepsis (METPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01207531
Recruitment Status : Unknown
Verified September 2010 by Chinese PLA General Hospital.
Recruitment status was:  Recruiting
First Posted : September 23, 2010
Last Update Posted : September 23, 2010
Information provided by:
Chinese PLA General Hospital

Brief Summary:
Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

Condition or disease

Detailed Description:
The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study
Study Start Date : July 2010
Estimated Primary Completion Date : November 2010
Estimated Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis
U.S. FDA Resources

Survival Group
Death group

Primary Outcome Measures :
  1. all cause mortality [ Time Frame: 28days after admited in ICU ]

Biospecimen Retention:   Samples Without DNA
human serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
within 24 hours after admited in ICU

Inclusion Criteria:

  • Clinical diagnosis of sepsis
  • Patients who agree with the study

Exclusion Criteria:

  • Aged <18 years;
  • Into the group who died within 24 hours;
  • Agranulocytosis (<0.5 × 109 / L);
  • Combined HIV infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01207531

Contact: Huijuan Wang, master +86 13466791738

China, Beijing
Chinese PLA General Hospital Recruiting
Beijing, Beijing, China, 100853
Sponsors and Collaborators
Chinese PLA General Hospital
Study Director: Lixin Xie, Doctor Pneumology Department of chinese PLA General Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lixin Xie, Pneumology Department of Chinese PLA General Hospital Identifier: NCT01207531     History of Changes
Other Study ID Numbers: 301PLAGH-2010915
First Posted: September 23, 2010    Key Record Dates
Last Update Posted: September 23, 2010
Last Verified: September 2010

Keywords provided by Chinese PLA General Hospital:

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes